Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Dane, Faysal; Ozgurdal, Kirhan; YALÇIN, ŞUAYİB; BENEKLİ, MUSTAFA; Aykan, Nuri; YÜCEL, İDRİS; ÖZKAN, METİN; EVRENSEL, TÜRKKAN; Sevinc, Alper; COŞKUN, HASAN; ŞANLI, ULUS; KARA, İSMAİL; Yumuk, Perran

doi:10.1136/bmjopen-2018-027665

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Atıf İçin Kopyala

Dane F., Ozgurdal K., YALÇIN Ş., BENEKLİ M., Aykan N. F., YÜCEL İ., ...Daha Fazla

BMJ OPEN, cilt.10, sa.3, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 10 Sayı: 3
Basım Tarihi: 2020
Doi Numarası: 10.1136/bmjopen-2018-027665
Dergi Adı: BMJ OPEN
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC.